Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Nils-Henning Ness¹ · Dirk Schriefer¹ · Rocco Haase¹ · Benjamin Ettle² · Tjalf Ziemssen¹

Published online: 13 May 2020
© The Author(s) 2020

Correction to: PharmacoEconomics
<https://doi.org/10.1007/s40273-020-00917-3>

In the original version of this article, the title of the article has been published incorrectly.

Previously read as

Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis

It should read as

“Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis”

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40273-020-00917-3>.

✉ Tjalf Ziemssen
Tjalf.Ziemssen@uniklinikum-dresden.de

¹ MS Center, Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Fetscherstr. 74, 01307 Dresden, Germany

² Novartis Pharma GmbH, Nuremberg, Germany